Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 229.61 Bil Enterprise Value: 416.39 Bil PE Ratio: 10.02 PB Ratio: 1.66 GF Score: 72/100

Royalty Pharma PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 03:00PM GMT
Release Date Price: MXN801
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great, everybody. Good morning again. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley, and pleased to have Royalty Pharma with us.

Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So, pleased to have the team with us. I'm going to turn it over to Pablo, who will make some opening comments, and then we'll jump into Q&A.

Pablo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Thank you, Matt, and thank you for the invitation to join you this morning. And I'd like just to start by saying that in this session, we're going to be making forward-looking statements, and I'd like to refer you to our 10-K. But with that, let me start, and I thought what I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot